Shenzhen Shankang Pharmaceutical Technology

Shenzhen Shankang Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the development of long-acting treatments for addiction and psychiatric disorders. The company's core technology focuses on sustained-release drug delivery systems, including biodegradable implants and microspheres. Its lead candidate, SK1801 (a naltrexone implant), is designed to treat opioid dependence and has reached the NDA submission stage in China. Shankang is also expanding its pipeline to address alcohol addiction and chronic pain management. The company aims to provide more effective, long-term therapeutic options to improve patient compliance in challenging CNS-related conditions.